Author: Rendic S.

Source: Expert Opinion on Drug Safety, Volume 3, Number 4, 1 July 2004 , pp. 379-380(2)

Publisher: Informa Healthcare

Abstract:

This conference was organised by Vision in Business, in order to address the issue that ‘more than 40% of drug preclinical failure is due to ADME-related issues and many drugs are later withdrawn because of unanticipated drug–drug interactions (C Masimirembwa, AstraZeneca Mölndal, Sweden). Academic and industrial scientists were brought together to discuss and present current knowledge/theories on subjects of importance in preclinical and clinical drug development. These included in vivo/in vitro correlations, approaches and experimental models used, in silico models and methods, metabolic databases and their application, as well as safety and financial outcomes. Participants were challenged by the issues covered and encouraged to share their own experiences and opinions during extensive discussions with other scientists.

Keywords: ADME; experimental models; in silico; in vitro; in vivo; metabolic databases; preclinical/clinical testing

Document Type: Meeting report

DOI: http://dx.doi.org/10.1517/14740338.3.4.379

Publication date: 2004-07-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Rendic S.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers